Patent 9597357 was granted and assigned to Sangamo Biosciences Inc. on March, 2017 by the United States Patent and Trademark Office.
Methods and compositions for modifying T-cells in which PD1 and/or CTLA-4 is repressed and/or inactivated using fusion proteins such as artificial transcription factors and nucleases.